Hay F, Linkowski P
Service de Psychiatrie, Hôpital Erasme, ULB, Bruxelles.
Rev Med Brux. 2004 Sep;25(4):A315-20.
The medications that appeared in the last two decades, offer praticians a wider choice than ever in the treatment of major depressive disorders. The aim of this article was first to compare tricyclic antidepressants and serotonine selective reuptake inhibitors. It was quite obvious that it was impossible to take no account of the birth of newer antidepressants. So we reviewed the efficacy--throughout their mechanims of action--of those different antidepressive agents, as well as their side-effects. One could think that the coming-out of molecules simpler to use, would facilitate the prescription. In fact, it does and it doesn't; it allows praticians, more than before, to accord with their clinical touch. That means that, at comparable efficacy, we now can choose therapeutic agents that fit more adequately a particular patient, his/her characteristics as well as his/her somatic and psychiatric history.
在过去二十年中出现的药物，为从业者在治疗重度抑郁症方面提供了比以往更广泛的选择。本文的目的首先是比较三环类抗抑郁药和血清素选择性再摄取抑制剂。很明显，完全不考虑新型抗抑郁药的出现是不可能的。因此，我们通过这些不同抗抑郁药的作用机制来回顾它们的疗效以及副作用。人们可能会认为，使用更简单的分子会使处方更容易。事实上，既是如此，也并非如此；它使从业者比以往更能顺应其临床触觉。这意味着，在疗效相当的情况下，我们现在可以选择更适合特定患者、其特征以及躯体和精神病史的治疗药物。
